MedTrace Logo

Zurig (Febuxostat) 40mg Efficacy and Safety Trial

NCT02600780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-08-01

No results posted yet for this study

Summary

Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid. The investigators conducted an interventional, two-arm, randomized, open label pilot study on patients with serum urate level ≥ 6.8 mg/dL. Patients were treated with Febuxostat 40 mg Tablets or Allopurinol 300 mg Tablets once daily dose for 90 days to determine the efficacy and safety of Febuxostat in comparison with Allopurinol in Hyperuricemic Subjects with or without Gout.

Conditions

  • Hyperuricemia

Interventions

DRUG

Febuxostat

Comparison of two anti-hyperuricemic molecules

DRUG

Allopurinol

Comparison of two anti-hyperuricemic molecules

Sponsors & Collaborators

  • Getz Pharma

    lead INDUSTRY

Principal Investigators

  • Khalid Mahmood, FCPS · Dow University of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-12-31
Completion
2015-03-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02600780 on ClinicalTrials.gov